Analysts Set Pfizer Inc. (NYSE:PFE) PT at $46.53
Pfizer Inc. (NYSE:PFE) has earned a consensus recommendation of “Hold” from the twenty-one brokerages that are covering the firm, Marketbeat Ratings reports. Fourteen equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $46.47.
A number of equities analysts recently weighed in on the stock. JPMorgan Chase & Co. lowered their price objective on shares of from GBX 97 ($1.27) to GBX 89 ($1.16) and set a “neutral” rating on the stock in a research report on Monday, June 17th. Goldman Sachs Group upgraded shares of Solaredge Technologies from a “sell” rating to a “neutral” rating and lifted their price objective for the company from $35.00 to $52.00 in a research report on Monday, June 17th. Bank of America assumed coverage on shares of Sogou in a research report on Monday, April 1st. They issued an “underperform” rating and a $5.60 price objective on the stock. Morgan Stanley set a $17.00 price objective on shares of BOX and gave the company a “hold” rating in a research report on Tuesday, June 4th. Finally, Zacks Investment Research upgraded shares of Green Brick Partners from a “sell” rating to a “hold” rating in a research report on Wednesday, April 10th.
In other news, insider Alexander R. Mackenzie sold 30,000 shares of Pfizer stock in a transaction on Thursday, June 20th. The stock was sold at an average price of $44.00, for a total transaction of $1,320,000.00. Following the completion of the transaction, the insider now owns 80,094 shares of the company’s stock, valued at approximately $3,524,136. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Pfizer Inc purchased 50,000 shares of the business’s stock in a transaction dated Monday, May 13th. The shares were purchased at an average cost of $17.00 per share, with a total value of $850,000.00. The disclosure for this purchase can be found here. 0.09% of the stock is currently owned by insiders.
NYSE:PFE traded down $0.29 during midday trading on Friday, reaching $42.77. The stock had a trading volume of 22,344,187 shares, compared to its average volume of 21,624,544. The business’s fifty day simple moving average is $43.09. Pfizer has a 12-month low of $37.12 and a 12-month high of $46.47. The company has a current ratio of 1.54, a quick ratio of 1.27 and a debt-to-equity ratio of 0.60. The stock has a market cap of $237.80 billion, a PE ratio of 14.26, a P/E/G ratio of 2.48 and a beta of 0.64.
Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, April 30th. The biopharmaceutical company reported $0.85 earnings per share for the quarter, beating analysts’ consensus estimates of $0.75 by $0.10. Pfizer had a net margin of 21.31% and a return on equity of 27.48%. The firm had revenue of $13.12 billion for the quarter, compared to analyst estimates of $13.01 billion. During the same period last year, the firm posted $0.77 EPS. Pfizer’s quarterly revenue was up 1.6% on a year-over-year basis. As a group, sell-side analysts expect that Pfizer will post 2.88 EPS for the current year.
The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 3rd. Shareholders of record on Friday, August 2nd will be given a dividend of $0.36 per share. The ex-dividend date of this dividend is Thursday, August 1st. This represents a $1.44 annualized dividend and a dividend yield of 3.37%. Pfizer’s payout ratio is currently 48.00%.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Featured Article: What is a death cross?
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.